Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7471957 | 0.98 | SIGMAR1 (0.51) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL7513389 | 0.92 | KEAP1 (0.48) | SIGMAR1TMEM97KEAP1SMN1; SMN2 | |
| SCHEMBL1306239 | 0.88 | ALOX15 (0.56) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL5841337 | 0.87 | SIGMAR1 (0.49) | SIGMAR1TMEM97 | |
| SCHEMBL17219705 | 0.86 | ALOX15 (0.54) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL6659238 | 0.85 | SIGMAR1 (0.61) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL6656817 | 0.85 | SIGMAR1 (0.57) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL24351554 | 0.85 | KEAP1 (0.42) | SIGMAR1TMEM97KEAP1SMN1; SMN2 | |
| SCHEMBL13091289 | 0.85 | KEAP1 (0.42) | SIGMAR1TMEM97KEAP1SMN1; SMN2 | |
| SCHEMBL6660619 | 0.83 | SIGMAR1 (0.56) | SIGMAR1TMEM97ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-6479482-B2 | 4-(3-((((3-(4-((3-METHYLBUTYL)AMINO)-1-PIPERIDINYL)PROPYL) -AMINO)-CARBONYL)AMINO)PHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5 -PYRIDINEDICARBOXYLIC ACID, DIMETHYL ESTER DIHYDROCHLORIDE, FOR EXAMPLE; ANOREXIANT; NEUROPEPTIDE Y (NPY) | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-12 | — | — | US | disclosed |
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2001085173-A1 | ALKYLAMINE DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | SIGMAR1 4305/4885TMEM97 2735/4885ABCB1 2919/4885 |
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY4R | SIGMAR1 108/4885TMEM97 1031/4885ABCB1 4625/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | SIGMAR1 4305/4885TMEM97 2735/4885ABCB1 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.